The complaint filed against ADMA Biologics, Inc. (NASDAQ: ADMA) centers on claims of deceptive business practices during the specified class period. Plaintiffs allege that the company utilized channel stuffing to artificially inflate revenue figures while failing to maintain adequate internal financial controls. By allegedly suppressing information about related party transactions, the firm argues that the company’s public statements regarding its operational health and prospects lacked a reasonable basis.

The Gross Law Firm has set a deadline of August 10, 2026, for shareholders to apply for the role of lead plaintiff. Participation in the action does not require this formal appointment, and there is no cost for investors to register their claims. Those who join the process will be enrolled in monitoring software to receive updates as the case moves through the court system.